MAO-B inhibitors
Monoamine oxidase B (MAO-B) inhibitors
The enzyme monoamine oxidase-B (MAO-B) is brain specific and involved in the breakdown of dopamine. Inhibitors of MAO-B therefore increase levels of dopamine only in the brain. The action of increasing natural levels of dopamine has seen MAO-B inhibitors, such as rasagiline and selegiline, developed as monotherapy for patients in the early stages of Parkinson’s disease (PD). In addition, MAO-B inhibitors can be used in combination with levodopa to increase levodopa-derived dopamine levels in patients with advanced PD. More information about MAO-B inhibitors is available on the EPDA website.
Editor's choice
This pilot phase 2, randomised, double-blind, placebo-controlled, parallel-group trial assessed the safety and efficacy of tesofensine, a triple monoamine reuptake inhibitor, in patients with...
Most recent articles
The role of rasagiline in the treatment of Parkinson’s disease
Rasagiline is a novel, potent, and irreversible monoamine oxidase type B (MAO-B) inhibitor. It inhibits MAO-B more potently than selegiline does, and...
Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study
The plasma concentration increased with the dosage, but no clear dose-response relationship was observed. Gastrointestinal tract and...
